Answers are grounded in this paper and cite their sources.
Biochemical analysis demonstrates LOXL2 selectively oxidizes lysine in unfolded collagen single strands over triple helices, indicating a mechanism for aberrant extracellular matrix stiffening.
Collagen cross-linking is essential for the structural integrity of the extracellular matrix. In several pathological conditions, the triple-helical core of collagen is disrupted, and proline-rich single strands occur. Lysyl oxidases (LOXs), enzymes that initiate cross-linking by catalyzing the oxidative deamination of lysine to allysine residues, are upregulated in disease. Surprisingly little is known about the selectivity of LOXs. LOX-initiated cross-linking is believed to occur exclusively in the unstructured terminal domains of collagen, the telopeptides. But is this really the case? Herein, we show, with a combination of tailored chemical probes, enzymatic assays, CD and NMR spectroscopic analyses, that LOXL2 oxidizes Lys in proline-rich single strands but not in triple helices. A comparison of Lys-containing collagen model peptides (CMPs) with Lys-containing telopeptides revealed comparable or higher oxidation rates in proline-rich segments. The data suggest that LOXL2-initiated cross-linking occurs in pathologically disrupted triple-helical domains, offering insights into aberrant extracellular matrix stiffening.
No takes yet. Share an insight, caveat, or question.
Poller et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: